DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Sarepta's - 1 Gavin Clark - 1 Gartner - 1 William Blair's Tim Lugo - 1 Leroy Leo - 1 Khushi - 1 Devika - 1
Top related locs:
U.S Bengaluru
Top related orgs:
Sarepta Therapeutics - 1 Food and Drug - 1 BioMarin Pharmaceuticals - 1 Thomson - 1

Search resuls for: "BioMarin Pharmaceuticals"


2 mentions found


☆ Sarepta slumps as concerns emerge around upcoming gene therapy data
  + stars: | 2023-06-23 | by ( ) www.reuters.com   time to read: +2 min
June 23 (Reuters) - Sarepta Therapeutics shares (SRPT.O) slumped 11% on Friday as some analysts voiced concerns that upcoming confirmatory trial data for its gene therapy to treat Duchenne muscular dystrophy (DMD) may not be enough to secure approval for expanded use. The U.S. health regulator had on Thursday granted Sarepta's Elevidys therapy accelerated approval to treat DMD patients aged between 4 and 5 years who can walk, contrary to the company's application for all patients who can walk. Sarepta's gene therapy is the first of its kind for DMD, an inherited progressive muscle-wasting disorder that almost always affects young boys. Elevidys, a one-time treatment, is expected to change the way that DMD patients are treated as current therapies require regular use. William Blair's Tim Lugo called the treatment "transformational for Duchenne's patients" and "a significant opportunity for Sarepta".
Persons: Sarepta's, Gavin Clark, Gartner, William Blair's Tim Lugo, Leroy Leo, Khushi, Devika Organizations: Sarepta Therapeutics, Food and Drug, BioMarin Pharmaceuticals, Thomson Locations: U.S, Bengaluru
☆ Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
  + stars: | 2023-05-17 | by ( David Carnevali | ) www.reuters.com   time to read: +4 min
Even shares of drug companies that do not have pending deals but are seen by analysts and investors as potential acquisition targets were hit. FTC officials did not respond to a request for comment on whether they planned to challenge any other pharmaceutical acquisitions. "We could see similar challenges to the Pfizer/Seagen deal" BMO analysts wrote in a note, arguing that the FTC could target other major drug companies with the resources to engage in bundling. UNDER THE RADARConversely, investors and analysts are hoping that smaller pharmaceutical acquisitions will continue to fly under the radar of regulators. Reporting by David Carnevali in New York; Editing by Greg Roumeliotis and Jamie FreedOur Standards: The Thomson Reuters Trust Principles.
0 next >>
Total: 2